1. Home
  2. Medical News
  3. Diabetes and Endocrinology
advertisement

GLP-1 Prescribing Rose as Adolescent Bariatric Surgery Declined

Simplified adolescent silhouettes represent young people eligible for obesity treatment in a restrained clinical
11/16/2026

Key Takeaways

  • Among surgery-eligible US adolescents during 2017–2025, 4.6% received at least one GLP-1 prescription and 0.39% underwent metabolic and bariatric surgery.
  • Quarterly GLP-1 prescribing rose substantially among adolescents eligible for metabolic and bariatric surgery.
  • Bariatric surgery use fell approximately 29% from its 2022 peak by late 2025.
  • By late 2025, GLP-1 prescribing was higher among privately insured adolescents than among those who were uninsured or self-pay.
Adolescents who meet guideline-based criteria for metabolic and bariatric surgery may have medication prescribing or an operation documented in their health records, but how often does either occur? Their records can show which treatments were ordered or performed, not how well either option works. For these adolescents, prescribing and procedure records allow investigators to examine documented use of both approaches.

Researchers examined electronic health records in their JAMA Pediatrics study of adolescent obesity treatment. Their cross-sectional analysis covered more than 1.4 million adolescents in the United States who met guideline-based criteria for metabolic and bariatric surgery during 2017–2025. Investigators assessed documentation of glucagon-like peptide-1 (GLP-1) receptor agonist prescriptions, including semaglutide and liraglutide, and bariatric procedures. They examined quarterly prescribing and surgery trends and compared prescribing by insurance status.

Quarterly GLP-1 prescribing increased from 301 prescriptions per 100,000 eligible adolescents in early 2017 to 10,676 per 100,000 at the end of 2025, an approximately 35-fold rise. These are rates during individual quarters, not the proportion of adolescents with at least one prescription over the full study period.

Bariatric surgery reached a quarterly peak of 189 procedures per 100,000 eligible adolescents in 2022, then declined through late 2025. Surgery and prescribing trends moved in different directions, although the records do not show that one treatment displaced the other. By late 2025, the GLP-1 prescribing rate among privately insured adolescents was 2.4 times that among uninsured or self-pay adolescents. Most eligible adolescents had neither treatment documented.

A GLP-1 prescription in an electronic health record documents an order, not whether a pharmacy dispensed the medication, an adolescent took it, or treatment continued. The rise in prescribing alongside the fall in surgery use cannot establish a causal relationship between the trends or show how well medication and surgery work for adolescents meeting surgery criteria. The insurance difference describes prescribing, rather than confirmed medication use.

The authors interpreted the limited recorded use of both treatment approaches as potentially reflecting barriers to access. The reasons eligible adolescents rarely had a prescription or surgery documented remain unestablished, according to the authors.

Clinician Questions

Did bariatric surgery rates differ by insurance status among surgery-eligible US adolescents?

Investigators described bariatric surgery rates as similar across insurance groups among US adolescents meeting guideline-based surgery criteria, in contrast to the insurance gradient in GLP-1 prescribing. Similar recorded surgery rates do not establish equal access to care.

Did adolescent-obesity semaglutide approval cause the decline in bariatric surgery among eligible US adolescents?

Semaglutide approval for adolescent obesity occurred in late 2022, around the time after which bariatric surgery rates declined among surgery-eligible US adolescents. Rode and colleagues did not establish that approval or increased GLP-1 prescribing caused surgery rates to fall.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free